Security record · archived quarter
TNDM
Tandem Diabetes Care, Inc. · Healthcare · Medical - Devices
1Tracked holders
-1Δ holders
34.13KShares held
$534,998Reported value
+0New positions
−2Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | -1 | 34.13K | $534,998 | n/a | −2 |
| Q2 2026 | 94 | -3 | 42.93M | $644.94M | +8 | −12 |
| Q1 2026 | 101 | +1 | 46.93M | $900.01M | +9 | −9 |
| Q4 2025 | 101 | +3 | 51.29M | $1.10B | +5 | −1 |
| Q3 2025 | 16 | -4 | 31.69M | $384.56M | n/a | −4 |
| Q2 2025 | 17 | +2 | 28.59M | $532.96M | +3 | −1 |
| Q1 2025 | 12 | -2 | 7.22M | $138.30M | n/a | −2 |
| Q4 2024 | 14 | -1 | 8.91M | $320.82M | n/a | −1 |
| Q3 2024 | 14 | +1 | 9.24M | $392.07M | +1 | n/a |
| Q2 2024 | 13 | n/a | 10.47M | $421.99M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 34.13K | +29.1% | $534,998 | 0.0% | ▲ Add | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Assenagon Asset Management… | $797,658 | was 0.0% |
| Assetmark, Inc | $26,408 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 51.40K shares, $985 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 06
SC 13G/A: Voya Financial, Inc.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API